All relevant data are within the paper and its Supporting Information files.

Introduction {#sec002}
============

Frozen shoulder, or adhesive capsulitis of the shoulder, is a common clinical condition characterized by insidious and progressive pain and the loss of active and passive range of motion (ROM) of the glenohumeral joint. The ROM of the shoulder is usually limited to a capsular pattern (mainly external rotation, followed by abduction and flexion; internal rotation is the least commonly involved). In addition, passive movements at or beyond the range limits are painful and resisted movements are not necessary to reproduce or aggravate the pain. The annual incidence of frozen shoulder is 3% to 5% in the general population and as high as 20% in people with diabetes \[[@pone.0118217.ref001]\]. The causes and mechanism of this syndrome remain unclear \[[@pone.0118217.ref002],[@pone.0118217.ref003]\].

A considerable proportion of patients with a frozen shoulder are treated with physiotherapy, nonsteroidal antiinflammatory drugs (NSAIDs), intraarticular injection of corticosteroids, and, recently, intraarticular injection of hyaluronate \[[@pone.0118217.ref004]--[@pone.0118217.ref007]\]. In persistent cases, more aggressive interventions, such as hydrodilation, manipulation under anesthesia, and arthroscopic or open capsule release, have been performed \[[@pone.0118217.ref008]--[@pone.0118217.ref011]\].

A variety of physical therapy interventions are used, including superficial application of heat or ice, ultrasound, interferential therapy, transcutaneous electrical nerve stimulation, active and passive ROM exercises, stretching exercises, proprioceptive neuromuscular facilitation techniques, and mobilization techniques \[[@pone.0118217.ref004],[@pone.0118217.ref005],[@pone.0118217.ref007],[@pone.0118217.ref012]\].

The intraarticular injection of corticosteroids and/or physical therapy programs, including exercise, physical agents such as heat and electrical therapy, and mobilization, are the most common treatment options for patients with a frozen shoulder \[[@pone.0118217.ref012]--[@pone.0118217.ref015]\]. However, the evidence that shows these options to improve pain and function or alter the natural history of frozen shoulder is controversial \[[@pone.0118217.ref016]\]. In addition, the side effects of corticosteroids are concerning.

Although therapeutic exercise, particularly stretching exercises and joint mobilization, remains the mainstay of conservative treatment for a frozen shoulder, shoulder pain during the intervention reduces the treatment effect. Manipulation or arthroscopic release under general anesthesia allows the pain experienced during the intervention to be avoided \[[@pone.0118217.ref008],[@pone.0118217.ref017]--[@pone.0118217.ref019]\]; however, an increased risk of humeral shaft fractures and failure to release the pathologic tissue have been reported \[[@pone.0118217.ref020]\]. Moreover, general anesthesia is a major procedure that has inherent risks, is relatively expensive, and may not be accepted by many patients with a frozen shoulder \[[@pone.0118217.ref020], [@pone.0118217.ref021]\].

A practical compromise of intraarticular injection of lidocaine followed by stretching exercises and joint mobilization may be a better method because it avoids the problems related to general anesthesia and allows the patient to be free of pain during the intervention. The purpose of this study was to compare the efficacy of intraarticular injection of lidocaine plus a physiotherapy program (INJPT) to physiotherapy alone (PT) in the treatment of a frozen shoulder. We hypothesized that there would be no significant difference in the efficacy of the INJPT and PT groups in the treatment of a frozen shoulder regarding demographic data and the primary and secondary outcome measures. A rejection of this null hypothesis may help us to examine whether the intraarticular injection of lidocaine immediately before a physiotherapy session could provide pain relief during the subsequent capsule-stretching and joint-mobilization program, thus achieving greater improvement in shoulder pain, ROM, functional ability, and quality of life than does physiotherapy alone.

Materials and Methods {#sec003}
=====================

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see [S1 CONSORT Checklist](#pone.0118217.s001){ref-type="supplementary-material"} and [S1 Protocol](#pone.0118217.s002){ref-type="supplementary-material"}.

Participants {#sec004}
------------

The following inclusion criteria were applied: a) a unilateral frozen shoulder, defined as greater than 50% limitation of passive ROM relative to the nonaffected side in one or more of three movement directions (i.e., abduction in the frontal plane, forward flexion in the sagittal plane, or external rotation in 0° of abduction) with a hard end feel \[[@pone.0118217.ref005],[@pone.0118217.ref022]\]; and b) symptoms that had lasted for at least 3 months. The following exclusion criteria were applied: a) previous manipulation of the affected shoulder under anesthesia; b) other rheumatic conditions involving the shoulder (e.g., rheumatoid arthritis, ankylosing spondylitis, or osteoarthritis); c) fracture or dislocation of the affected shoulder; d) previous shoulder surgery; e) Hill-Sachs lesion, severe osteoporosis, or malignancies in the shoulder region); f) neurologic deficits affecting shoulder function; g) disorders of the cervical spine, elbow, wrist, or hand; h) a history of allergy to lidocaine; i) pregnancy or lactation; and j) corticosteroid injection in the affected shoulder during the preceding 4 weeks.

Design {#sec005}
------

This prospective and randomized controlled study recruited patients with a frozen shoulder from the outpatient clinic of the Department of Physical Medicine and Rehabilitation at Shin Kong Wu Ho-Su Memorial Hospital. The study project and consent form were approved by the hospital's ethics committee. From April 2010 through December 2013, we initiated this clinical trial, which was institutional review board--registered from December 2009 to November 2010, and from December 2012 to December 2013. The data reported in this study were collected from patients who were enrolled from January 2013 to December 2013. All of the participants gave written informed consent before they were randomized and baseline measurements were performed. The authors confirm that all ongoing and related trials for this intervention are registered. The patients were randomized to either the PT group or the INJPT group using a table of random numbers. After baseline assessment, sequentially numbered, opaque, sealed envelopes were opened by a research assistant. All injections were administered by a senior physician (L-F, H), who was a board-certified physiatrist and rheumatologist and who had also completed basic and advanced courses in Cyriax's International Orthopedic Medicine.

Interventions {#sec006}
-------------

In the PT group, each patient underwent electrical therapy and the use of hot packs, followed by stretching exercises and joint mobilization, which were performed by a senior physical therapist three times per week for 3 months or until satisfactory results were achieved. In the INJPT group, lidocaine was injected into the affected shoulder 10 to 20 minutes before the physiotherapy session, but the injection was performed only when the patient suffered from severe shoulder pain (pain score of 7 cm or higher on a 10-cm visual analog scale) during capsule stretching or before posterior joint mobilization. For the injection, the patient was placed in a sitting position with the arm across the abdomen and the elbow flexed to a right angle. The examiner placed an index finger at the coracoid process and a thumb dorsally on the posterior angle where the scapular spine meets the acromion. After sterilization, a 1.5-inch 25-gauge needle was fitted on a 3-ml syringe filled with 3 ml of 1% lidocaine. The same physiotherapy programs were used in both the INJPT and PT groups and were conducted by the same physical therapist. The injections were repeated at a frequency of not more than twice per week and the total number of injections was limited to 10.

Demographic data {#sec007}
----------------

At baseline, data were recorded regarding age, sex, employment status, sports and leisure activities, and history of diabetes mellitus or other medical disorders (items related to the causes of a frozen shoulder), as well as data regarding the duration of complaints, previous treatments, and current pain medications (items related to the stage or severity of the frozen shoulder).

Shoulder radiography and ultrasonography {#sec008}
----------------------------------------

To exclude patients with fractures, osteoarthritis, calcification of the tendons, anatomical variants of the acromion, bone tumors, and osteonecrosis, anteroposterior and lateral shoulder radiographs were obtained. We also carried out ultrasound scanning (LOGIQ P5; General Electric Company) of the shoulder, including imaging of the biceps, subscapularis, supraspinatus, and infraspinatus tendons, subdeltoid bursa, and acromioclavicular joint, to rule out rotator cuff tears, tendinopathy, calcification of the tendons, and subdeltoid lesions.

Outcome measures {#sec009}
----------------

The active and passive ROMs of the affected shoulder, including flexion, abduction, internal rotation, and external rotation, were measured with a goniometer by a senior physical therapist who did not know the group assignments of the patients. It has been reported that these goniometric measurements of the shoulder are highly reliable if the measurements are conducted by the same physical therapist \[[@pone.0118217.ref023]\].

We also used the Shoulder Disability Questionnaire (SDQ) \[[@pone.0118217.ref024]\] and the Shoulder Pain and Disability Index (SPADI) \[[@pone.0118217.ref024]\] to quantify the level of pain and disability and the 36-item Short-Form Health Survey (SF-36) to describe general health status. The SDQ includes 16 items developed to evaluate the self-assessed functional limitation of patients with shoulder disorders. The score ranges from 0 to 100, with a higher score indicating a worse condition \[[@pone.0118217.ref025]\]. The SPADI is a self-administered questionnaire that includes 13 items in two subscales. By averaging the scores from the 5 items of the pain subscale and 8 items of the disability subscale, a score of 0 to 100 is obtained. A high score indicates greater pain or greater disability.

As a general health measurement, the SF-36 comprises eight subscales: physical functioning, role-physical, bodily pain, general health perception, vitality, social functioning, role-emotional, and mental health. A score of 0 to 100 is obtained from each of these subscales, with higher scores indicating better health. From these eight health concepts, two summary scores, one for physical health and one for mental health, can be computed \[[@pone.0118217.ref026]\].

The patients were evaluated at baseline and at 1, 2, 3, 4, and 6 months after the start of treatment. The deviations of the trial outcomes from the original study protocol were the secondary outcome measures. The Shoulder Rating Questionnaire was replaced by the SPADI, because the SPADI is more commonly used and its validity and reliability are well established. The primary outcome measures were the active and passive ROM of the affected shoulder, and the secondary outcome measures were the scores on the SDQ, SPADI, and SF-36.

Statistical analysis {#sec010}
--------------------

An a priori power analysis based on pilot results determined that 27 subjects per group considering the active ROM of flexion and 30 subjects per group considering the active ROM of external rotation would yield a power of 0.8 at a significance level of 0.05. A chi-square test was used to examine the differences in the demographic data between the PT and INJPT groups for categorical variables, including gender, exercise habits, and history of NSAID use. An independent *t* test was used to examine the differences in the demographic data between the PT and INJPT groups for continuous variables, including age, weight, height, and disease duration. The chi-square test was used to test the null hypothesis that there was no significant difference between the PT and INJPT groups in the baseline variables, including gender, exercise habits, and history of NSAID use. The *t* test was used to test the null hypothesis that there was no significant difference between the PT and INJPT groups in the baseline variables, including age, weight, height, and disease duration. For the primary and secondary outcome measurements, the Kolgomorov-Smirnov test was performed to check for normal distribution and homogeneity of variance was checked with Levine's *F* test. As the assumption of normality was not met for most of the outcome measures, the Mann-Whitney *U* test was used to examine the group effects (i.e., PT and INJPT) and Friedman's test was used to examine the time effects (evaluation times: before and 1, 2, 3, 4, and 6 months after the start of treatment) on ROM and the SDQ, SPADI, and SF-36 results. All significance levels were set at an α level of 0.05 for comparison of the demographic data in the PT and INJPT groups. Bonferroni adjustments were performed for corrected α levels of 0.025 for the time effects (i.e., calculated for each pairwise comparison in the PT and INJPT groups) and corrected α levels of 0.008 for the group effects (i.e., calculated for six pairwise comparisons for the six evaluation times). SPSS version 19.0 (SPSS Inc., Chicago, USA) was used for all statistical analyses.

Results {#sec011}
=======

Baseline characteristics {#sec012}
------------------------

We recruited 106 patients for our study. Fifteen were excluded because of the exclusion criteria and 19 refused to sign the consent form. As a result, the study included 36 subjects in the PT group and 36 subjects in the INJPT group ([Fig. 1](#pone.0118217.g001){ref-type="fig"}). Of these subjects, three members of each group withdrew during the follow-up period for reasons including traumatic brain injury, acute myocardial infarction, and loss of interest. Thus, 33 subjects in each group completed the study. The baseline characteristics of the participants in the PT and INJPT groups are listed in [Table 1](#pone.0118217.t001){ref-type="table"}; no significant differences in the demographic or baseline measurements were found ([Table 1](#pone.0118217.t001){ref-type="table"}). The average number of injections in the INJPT group was 5.94 ± 2.09 (range, 3 to 10). Mild treatment-related pain in the affected shoulder lasting for 1 to 2 days was reported in two subjects in the INJPT group.

![The consolidated standards for reporting trials: a flow diagram of the study.\
Abbreviations: PT, physiotherapy group; INJPT, lidocaine injection plus physiotherapy group.](pone.0118217.g001){#pone.0118217.g001}

10.1371/journal.pone.0118217.t001

###### Demographic and clinical characteristics of the subjects.

![](pone.0118217.t001){#pone.0118217.t001g}

  Characteristic              PT Group (n = 33)                              INJPT Group (n = 33)                 
  --------------------------- ---------------------------------------------- ---------------------- ------------- -----
  Sex                         male                                           8                      7             .76
                              female                                         25                     26            
  Exercise habits             yes                                            11                     13            .60
                              no                                             22                     20            
  NSAID                       yes                                            17                     21            .31
                              no                                             16                     12            
                              *P* [^*b*^](#t001fn004){ref-type="table-fn"}                                        
  Age (y)                                                                    56.41 ±9.44            54.88 ±7.06   .85
  Weight (kg)                 62.09 ±9.69                                    59.61 ± 10.91          .33           
  Height (cm)                 161.09 ±8.37                                   159.79 ± 7.87          .51           
  Disease duration (months)   4.54 ±3.25                                     6.12 ± 5.05            .14           

NOTE. Values are expressed as means ± SD or numbers.

Group differences were analyzed using either a chi-squared test or an independent *t* test.

*P* ^*a*^\<.05, significant difference from the chi-square

*P* ^*b*^\<.05, significant difference from the independent t test

Abbreviations: PT, physical therapy; INJPT, injection plus physical therapy; NSAID, non-steroidal anti-inflammatory drug.

Range of motion {#sec013}
---------------

In both groups, both active and passive ROM (flexion, abduction, external rotation, and internal rotation) improved over time after treatment ([Fig. 2](#pone.0118217.g002){ref-type="fig"}). In the between-group comparison, significant group effects were observed for the active ROM in flexion and in external rotation at 3, 4, and 6 months after treatment. Significant group effects were observed for the passive ROM in flexion at 3, 4, and 6 months after treatment and in external rotation at 4 and 6 months after treatment. Higher values for these active and passive shoulder ROMs were found in the INJPT group than in the PT group ([Fig. 2](#pone.0118217.g002){ref-type="fig"}). No significant group effect was observed for internal rotation at any assessment time in either the active or passive ROM.

![Comparisons of the active and passive ROMs between the groups.\
Shown as bar charts for (a) flexion, (b) abduction, (c) external rotation, and (d) internal rotation for active ROM and for (e) flexion, (f) abduction, (g) external rotation, and (h) internal rotation for passive ROM with the corresponding standard deviations represented as error bars. An asterisk indicates significant differences between groups (*P*\<0.008). For the evaluation times (evaluation times: before and 1, 2, 3, 4, and 6 months after the start of treatment), a right arrow above the graph indicates a significant, linearly increasing trend, whereas a left arrow indicates a significant, linearly decreasing trend (*P*\<0.025). (Black bar: the PT group; gray bar: the INJPT group). Group differences were analyzed using Mann-Whitney *U* test. Treatment time effects were analyzed using Friedman\'s test for two groups respectively. Abbreviations: PT, physical therapy; INJPT, injection plus physical therapy.](pone.0118217.g002){#pone.0118217.g002}

Pain and disability {#sec014}
-------------------

As time passed, the pain and disability after treatment decreased in both groups. For both groups, the pain-related SDQ results ([Table 2](#pone.0118217.t002){ref-type="table"}) indicated that symptoms decreased as time increased after treatment. The SPADI results also indicated that pain, disability, and the total score significantly decreased with time for both groups ([Table 2](#pone.0118217.t002){ref-type="table"}), suggesting that improvements in shoulder-related pain and disability occurred in both groups. In the between-group comparisons, significant group effects favoring the INJPT group were observed for the SDQ at 6 months after treatment and for the SPADI (pain, disability, and total score) at 1 month after treatment ([Table 3](#pone.0118217.t003){ref-type="table"}).

10.1371/journal.pone.0118217.t002

###### Effect of time on the secondary outcome measurements.

![](pone.0118217.t002){#pone.0118217.t002g}

  Scores on Questionnaires   Group                  Evaluation Time   Time Effects                                                                                                                                                                  
  -------------------------- ---------------------- ----------------- --------------- --------------- --------------- --------------- --------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
  SDQ                        PT                     48.20 ± 19.03     35.70 ± 18.81   29.28 ± 20.05   29.83 ± 18.96   25.33 ± 18.75   22.61 ± 17.94   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  INJPT                      39.06 ± 7.99           35.03 ± 8.04      27.02 ± 12.4    24.38 ± 14.33   19.86 ± 14.91   10.58 ± 15.72   0.000 ∼0.087    \<. 001[\*](#t002fn002){ref-type="table-fn"}                                                  
  SPADI                      Pain                   PT                46.36 ± 23.01   32.73 ± 18.66   28.30 ± 17.70   29.82 ± 18.72   24.91 ± 16.56   21.79 ± 16.31                                  0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}
                             INJPT                  55.27 ± 22.43     49.45 ± 27.92   31.03 ± 18.08   25.76 ± 16.69   22.91 ± 18.39   16.73 ± 14.27   0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  Disa                       PT                     36.25 ± 18.47     28.03 ± 18.50   23.00 ± 17.24   21.98 ± 19.38   18.77 ± 17.42   16.86 ± 14.48   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
                             INJPT                  54.55 ± 22.47     45.04 ± 22.79   30.34 ± 19.63   26.25 ± 19.78   21.97 ± 19.49   16.74 ± 16.60   0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  Total                      PT                     41.31 ± 19.68     30.38 ± 17.85   25.65 ± 16.83   25.44 ± 18.94   21.31 ± 15.99   19.32 ± 14.75   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
                             INJPT                  54.91 ± 20.48     47.25 ± 22.34   30.69 ± 17.93   26.00 ± 17.65   22.44 ± 17.88   16.73 ± 14.81   0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  SF-36                      Physical functioning   PT                75.61 ± 15.45   77.88 ± 16.25   79.70 ± 13.93   79.70 ± 14.13   81.12 ± 15.18   83.30 ± 13.87                                  0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}
                             INJPT                  71.21±18.79       73.94±19.83     76.67±17.93     76.97±18.03     80.76±18.33     81.67±17.62     0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  Role-physical              PT                     44.70 ± 39.80     57.88 ± 40.29   63.67 ± 34.60   64.61 ± 32.10   65.36 ± 32.27   75.33 ± 35.82   0.000 ∼0.146                                   \<.001[\*](#t002fn002){ref-type="table-fn"}    
                             INJPT                  37.88 ± 41.98     46.97 ± 46.25   65.15 ± 42.82   62.88 ± 41.51   71.97 ± 38.91   75.76 ± 39.27   0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  Bodily pain                PT                     52.58 ± 13.69     62.27 ± 17.42   66.61 ± 15.97   62.39 ± 16.45   67.33 ± 14.81   70.73 ± 17.91   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
                             INJPT                  44.55 ± 18.80     55.24 ± 18.46   61.70 ± 15.79   65.85 ± 15.49   66.39 ± 14.55   70.06 ± 17.87   0.000 ∼0.087                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
  General health             PT                     64.18 ± 19.83     58.52 ± 19.70   62.12 ± 18.57   59.91 ± 18.52   62.03 ± 80.82   64.76 ± 18.03   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
                             INJPT                  58.61 ± 19.85     60.42 ± 20.05   65.39 ± 18.98   64.27 ± 20.10   65.48 ± 19.38   64.76 ± 19.07   0.000 ∼0.142                                   .006[\*](#t002fn002){ref-type="table-fn"}      
  Vitality                   PT                     63.79 ± 19.29     62.88 ± 17.28   58.94 ± 14.83   60.88 ± 16.10   62.45 ± 16.66   65.97 ± 15.57   0.000 ∼0.146                                   \<. 001[\*](#t002fn002){ref-type="table-fn"}   
                             INJPT                  55.91 ± 21.45     58.18 ± 18.24   59.39 ± 19.91   61.06 ± 20.53   61.52 ± 18.81   61.97 ± 20.42   0.407 ∼0.744                                   .577                                           
  Social functioning         PT                     79.17 ± 19.43     81.06 ± 22.78   80.95 ± 14.34   82.36 ± 12.72   84.77 ± 13.82   87.27 ± 13.02   0.000 ∼0.146                                   .001[\*](#t002fn002){ref-type="table-fn"}      
                             INJPT                  79.55 ± 19.47     80.68 ± 15.96   81.06 ± 18.25   81.82 ± 14.01   85.23 ± 12.29   84.09 ± 12.99   0.050 ∼0.313                                   .272                                           
  Role-emotional             PT                     74.75 ± 37.30     79.80 ± 35.30   74.14 ± 37.74   77.27 ± 35.38   75.19 ± 35.66   79.75 ± 33.29   0.302 ∼0.751                                   .474                                           
                             INJPT                  67.68 ± 42.07     77.78 ± 37.88   76.77 ± 37.72   79.8 ± 38.13    83.84 ± 32.41   86.87 ± 28.79   0.000 ∼0.087                                   .003[\*](#t002fn002){ref-type="table-fn"}      
  Mental health              PT                     68.61 ± 19.80     69.33 ± 18.35   66.48 ± 16.65   68.33 ± 17.45   69.97 ± 17.47   71.42 ± 17.17   0.000 ∼0.146                                   .002[\*](#t002fn002){ref-type="table-fn"}      
                             INJPT                  68.85 ± 20.90     69.33 ± 18.57   67.03 ± 19.47   68.73 ± 18.67   67.88 ± 18.53   64.97 ± 21.05   0.811 ∼1.000                                   .845                                           

NOTE. Values are expressed as means ± SD or numbers.

\*Treatment time effects were analyzed using Friedman\'s test for two groups respectively.

\**P*\<.025, significant difference

Abbreviations: CI., confidence interval; PT, physical therapy; INJPT, injection plus physical therapy; SDQ, Shoulder Disability Questionnaire; SPADI, Shoulder Pain and Disability Index; Disa, Disability; SF-36, 36-item Short-Form Health Survey

10.1371/journal.pone.0118217.t003

###### Effect of group on the secondary outcome measurements.

![](pone.0118217.t003){#pone.0118217.t003g}

                                                              PT Group        INJPT Group     Mean Difference of 95% CI.                  *P* [\*](#t003fn003){ref-type="table-fn"}
  -------------------- ---------------------- --------------- --------------- --------------- ------------------------------------------- --------------------------------------------
  SDQ                                         Pre-treatment   43.62 ± 17.55   39.06 ± 7.99    0.000 ∼0.096                                .116
                                              Post-1 month    35.70 ± 18.81   35.03 ± 8.04    0.956 ∼1.000                                .990
                                              Post-2 months   29.28 ± 20.05   27.02 ± 12.4    0.395 ∼0.636                                .590
                                              Post-3 months   29.83 ± 18.96   24.38 ± 14.33   0.126 ∼0.328                                .192
                                              Post-4 months   25.33 ± 18.75   19.86 ± 14.91   0.290 ∼0.528                                .242
                                              Post-6 months   22.61 ± 17.94   10.58 ± 15.72   0.000 ∼0.044                                . 007[\*](#t003fn002){ref-type="table-fn"}
  SPADI                Pain                   Pre-treatment   55.27 ± 22.43   46.36 ± 23.01   0.000 ∼0.096                                .147
                       Post-1 month           49.45 ± 27.92   32.73 ± 18.66   0.000 ∼0.044    .004[\*](#t003fn002){ref-type="table-fn"}   
                       Post-2 months          31.03 ± 18.08   28.30 ± 17.70   0.504 ∼0.738    .639                                        
                       Post-3 months          25.76 ± 16.69   29.82 ± 18.72   0.276 ∼0.512    .379                                        
                       Post-4 months          22.91 ± 18.39   24.91 ± 16.56   0.457 ∼0.695    .508                                        
                       Post-6 months          16.73 ± 14.27   21.79 ± 16.31   0.126 ∼0.328    .199                                        
  Disa                 Pre-treatment          47.35 ± 18.71   36.25 ± 18.47   0.000 ∼0.063    .162                                        
                       Post-1 month           45.04 ± 22.79   28.03 ± 18.50   0.000 ∼0.044    .002[\*](#t003fn002){ref-type="table-fn"}   
                       Post-2 months          30.34 ± 19.63   23.00 ± 17.24   0.065 ∼0.238    .154                                        
                       Post-3 months          26.25 ± 19.78   21.98 ± 19.38   0.320 ∼0.559    .415                                        
                       Post-4 months          21.97 ± 19.49   18.77 ± 17.42   0.457 ∼0.695    .585                                        
                       Post-6 months          16.74 ± 16.60   16.86 ± 14.48   0.457 ∼0.695    .676                                        
                       Total                  Pre-treatment   49.37 ± 17.35   41.31 ± 19.68   0.000 ∼0.073                                .185
                       Post-1 month           47.25 ± 22.34   30.38 ± 17.85   0.000 ∼0.044    .002[\*](#t003fn002){ref-type="table-fn"}   
                       Post-2 months          30.69 ± 17.93   25.65 ± 16.83   0.139 ∼0.346    .256                                        
                       Post-3 months          26.00 ± 17.65   25.44 ± 18.94   0.860 ∼0.988    .868                                        
                       Post-4 months          22.44 ± 17.88   21.31 ± 15.99   0.840 ∼0.978    .913                                        
                       Post-6 months          16.73 ± 14.81   19.32 ± 14.75   0.441 ∼0.680    .473                                        
  SF-36                Physical functioning   Pre-treatment   75.61 ± 15.45   71.21±18.79     0.364 ∼0.605                                .485
                       Post-1 month           77.88 ± 16.25   73.94±19.83     0.349 ∼0.590    .370                                        
                       Post-2 months          79.70 ± 13.93   76.67±17.93     0.334 ∼0.575    .469                                        
                       Post-3 months          79.70 ± 14.13   76.97±18.03     0.457 ∼0.695    .642                                        
                       Post-4 months          81.12 ± 15.18   80.76±18.33     0.689 ∼0.887    .842                                        
                       Post-6 months          83.30 ± 13.87   81.67±17.62     0.840 ∼0.978    .954                                        
  Role-physical        Pre-treatment          44.70 ± 39.80   37.88 ± 41.98   0.364 ∼0.605    .502                                        
                       Post-1 month           57.88 ± 40.29   46.97 ± 46.25   0.395 ∼0.636    .556                                        
                       Post-2 months          63.67 ± 34.60   65.15 ± 42.82   0.165 ∼0.380    .270                                        
                       Post-3 months          64.61 ± 32.10   62.88 ± 41.51   0.457 ∼0.695    .547                                        
                       Post-4 months          65.36 ± 32.27   71.97 ± 38.91   0.032 ∼0.180    .061                                        
                       Post-6 months          75.33 ± 35.82   75.76 ± 39.27   0.065 ∼0.238    .094                                        
  Bodily pain          Pre-treatment          52.58 ± 13.69   44.55 ± 18.80   0.012 ∼0.140    .086                                        
                       Post-1 month           62.27 ± 17.42   55.24 ± 18.46   0.022 ∼0.160    .136                                        
                       Post-2 months          66.61 ± 15.97   61.70 ± 15.79   0.042 ∼0.200    .139                                        
                       Post-3 months          62.39 ± 16.45   65.85 ± 15.49   0.654 ∼0.861    .713                                        
                       Post-4 months          67.33 ± 14.81   66.39 ± 14.55   0.441 ∼0.680    .485                                        
                       Post-6 months          70.73 ± 17.91   70.06 ± 17.87   0.654 ∼0.861    .661                                        
  General health       Pre-treatment          64.18 ± 19.83   58.61 ± 19.85   0.139 ∼0.346    .264                                        
                       Post-1 month           58.52 ± 19.70   60.42 ± 20.05   0.603 ∼0.821    .621                                        
                       Post-2 months          62.12 ± 18.57   65.39 ± 18.98   0.457 ∼0.695    .550                                        
                       Post-3 months          59.91 ± 18.52   64.27 ± 20.10   0.537 ∼0.766    .608                                        
                       Post-4 months          62.03 ± 80.82   65.48 ± 19.38   0.504 ∼0.738    .551                                        
                       Post-6 months          64.76 ± 18.03   64.76 ± 19.07   0.840 ∼0.978    .862                                        
  Vitality             Pre-treatment          63.79 ± 19.29   55.91 ± 21.45   0.042 ∼0.200    .164                                        
                       Post-1 month           62.88 ± 17.28   58.18 ± 18.24   0.290 ∼0.528    .350                                        
                       Post-2 months          58.94 ± 14.83   59.39 ± 19.91   0.956 ∼1.000    .995                                        
                       Post-3 months          60.88 ± 16.10   61.06 ± 20.53   0.860 ∼0.988    .954                                        
                       Post-4 months          62.45 ± 16.66   61.52 ± 18.81   0.603 ∼0.821    .686                                        
                       Post-6 months          65.97 ± 15.57   61.97 ± 20.42   0.234 ∼0.463    .375                                        
  Social functioning   Pre-treatment          79.17 ± 19.43   79.55 ± 19.47   0.840 ∼0.978    .916                                        
                       Post-1 month           81.06 ± 22.78   80.68 ± 15.96   0.441 ∼0.680    .500                                        
                       Post-2 months          80.95 ± 14.34   81.06 ± 18.25   0.781 ∼0.946    .833                                        
                       Post-3 months          82.36 ± 12.72   81.82 ± 14.01   0.620 ∼0.835    .768                                        
                       Post-4 months          84.77 ± 13.82   85.23 ± 12.29   0.569 ∼0.794    .637                                        
                       Post-6 months          87.27 ± 13.02   84.09 ± 12.99   0.077 ∼0.257    .156                                        
  Role-emotional       Pre-treatment          74.75 ± 37.30   67.68 ± 42.07   0.320 ∼0.559    .516                                        
                       Post-1 month           79.80 ± 35.30   77.78 ± 37.88   0.840 ∼0.978    .912                                        
                       Post-2 months          74.14 ± 37.74   76.77 ± 37.72   0.504 ∼0.738    .606                                        
                       Post-3 months          77.27 ± 35.38   79.8 ± 38.13    0.248 ∼0.480    .376                                        
                       Post-4 months          75.19 ± 35.66   83.84 ± 32.41   0.054 ∼0.219    .103                                        
                       Post-6 months          79.75 ± 33.29   86.87 ± 28.79   0.126 ∼0.328    .177                                        
  Mental health        Pre-treatment          68.61 ± 19.80   68.85 ± 20.90   0.781 ∼0.946    .842                                        
                       Post-1 month           69.33 ± 18.35   69.33 ± 18.57   0.586 ∼0.808    .723                                        
                       Post-2 months          66.48 ± 16.65   67.03 ± 19.47   0.882 ∼0.997    .913                                        
                       Post-3 months          68.33 ± 17.45   68.73 ± 18.67   0.840 ∼0.978    .933                                        
                       Post-4 months          69.97 ± 17.47   67.88 ± 18.53   0.349 ∼0.590    .504                                        
                       Post-6 months          71.42 ± 17.17   64.97 ± 21.05   0.139 ∼0.346    .194                                        

NOTE. Values are expressed as means ± SD or numbers.

\*Group differences were analyzed using Mann-Whitney U test.

\**P*\<.008, significant difference

Abbreviations: CI., confidence interval; PT, physical therapy; INJPT, injection plus physical therapy; SDQ, Shoulder Disability Questionnaire; SPADI, Shoulder Pain and Disability Index; Disa, Disability; SF-36, 36-item Short-Form Health Survey.

Quality of life {#sec015}
---------------

Significantly increased scores for physical functioning, role-physical, bodily pain, and general health were observed in both groups with increasing time after treatment. There were also significant improvements in vitality, social functioning, and mental health in the PT group, whereas the scores for role-emotional remained statistically unchanged over time in the PT group ([Table 2](#pone.0118217.t002){ref-type="table"}). In the group comparison, no significant group effect was found at any assessment time for these quality of life items ([Table 3](#pone.0118217.t003){ref-type="table"}).

Discussion {#sec016}
==========

To our knowledge, this randomized controlled trial is the first to confirm the additional benefit of intraarticular injection of lidocaine immediately before a physiotherapy session in the treatment of a frozen shoulder. Although intraarticular injection of corticosteroids or hyaluronic acid has been previously reported for this condition, studies of intraarticular injection of lidocaine to relieve pain during subsequent capsule stretching or joint mobilization have not yet been reported. The combination of intraarticular injection of corticosteroids and physiotherapy in the treatment of a frozen shoulder has been reported, but no temporal relationship between the injection and the physiotherapy session has been established. Other strengths of our study included randomization of the subjects and comprehensive evaluations of pain, functional ability, and quality of life over a relatively long period compared with previous studies \[[@pone.0118217.ref008],[@pone.0118217.ref013],[@pone.0118217.ref027]\].

Neviaser and Hannafin defined four stages of frozen shoulder \[[@pone.0118217.ref007]\]. Stage 1 is characterized by a gradual onset of pain with no limitations of movement after the pain is relieved with an intraarticular injection of anesthetic. Arthroscopy during this stage reveals a fibrinous inflammatory reaction without adhesion formation. Stage 2 (the freezing stage) is characterized by a combination of synovitis and progressive capsular contracture. Stage 3 (the frozen stage) is the stage of maturation, in which the main patient complaint is significant joint stiffness; a limited ROM is also prominent. Stage 4 (the thawing stage) is the chronic stage; the pain is minimal and gradual improvements in motion can occur \[[@pone.0118217.ref002],[@pone.0118217.ref007]\]. All of our study subjects had a limited ROM with a hard end feel and synovitis was either minimal or absent. Although precise clinical classification is difficult, all of our study subjects were in stages 2 to 4; in these three stages, physical modalities followed by stretching and joint mobilization are mostly recommended. However, physiotherapy is not always effective because of the pain experienced during exercise programs \[[@pone.0118217.ref028]\]. An injection of lidocaine immediately before stretching or mobilization exercises can effectively relieve pain during the exercise programs, thus enhancing the effectiveness of the physiotherapy. Another cause of the enhanced effectiveness might be the capsular stretching effect from the injection of 3 ml of 1% lidocaine into the joint capsule.

In patients with a frozen shoulder, the limitations in the ROM usually follow a capsular pattern, i.e., external rotation is involved earliest and most severely, followed by abduction and flexion, and internal rotation is the least commonly involved. With regard to the primary outcome measurements, our results showed significantly greater improvements in external rotation and flexion in the INJPT group, which indicates an additional effect of the lidocaine injection. With regard to secondary outcome measurements, no group difference was observed in the SF-36, but the INJPT group showed superior results for some items of the SDQ and SPADI. The reason for this difference may be that the SF-36 is a general measurement of quality of life and a change in shoulder ROM may not reflect changes in the SF-36. The SDQ and SPADI were designed for the evaluation of shoulder disorders and are more sensitive to the improvement of shoulder ROM.

Lidocaine hydrochloride, the most widely used local anesthetic, is a reversible blocker of conduction along the small nerve fibers that carry pain and autonomic impulses. The effects occur within seconds and the block lasts for approximately 60 to 90 minutes (for 1% lidocaine) \[[@pone.0118217.ref029]\]. In our study, stretching or mobilization of the joint was performed 10 to 20 minutes after the intraarticular injection of lidocaine; therefore, the pain experienced during the exercise can be blocked by lidocaine. The use of lidocaine is much safer than that of glucocorticoids, which are associated with many local and systemic side effects, including steroid arthropathy, joint and soft tissue infection, subcutaneous atrophy, skin depigmentation, suppression of the hypothalamic-pituitary axis, and impaired diabetic control \[[@pone.0118217.ref030],[@pone.0118217.ref031]\]. Moreover, intraarticular glucocorticoid injection may be effective only in the inflammatory stage of frozen shoulder and the use of corticosteroid injection in the fibrotic stage may be inappropriate.

Over the past few years, chondrotoxicity due to intraarticular injection of local anesthetic has been reported. One clinical report showed that a high-dose infusion of intraarticular local anesthetic (377 ml of 0.5% bupivacaine) by a pain pump was related to chondrotoxicity \[[@pone.0118217.ref032]\]. Another in vitro study demonstrated a significant decrease in chondrocyte viability after single-dose 1% lidocaine injection \[[@pone.0118217.ref033]\]. Although chondrotoxicity caused by intraarticular injection of local anesthetics is level IV evidence, to avoid injury to the articular cartilage, we injected the affected shoulder with only 3 ml of 1% lidocaine and kept the number of injections as low as possible. Injections were performed only when passive capsule stretching induced shoulder pain greater than 7 on a 10-cm visual analog pain scale, with a limit of 10 total injections. Two subjects in the INJPT group complained of pain after the physiotherapy sessions, but the symptoms subsided after the intensity of capsule stretching and joint mobilization was decreased. Because of the analgesic effect of the lidocaine, the patients lost the ability to protect their bodies from extrinsic injury. We recommend that manual techniques (following lidocaine injection) should be applied with caution (e.g., guided by the end feel) or by an experienced doctor or physical therapist. No cases of infection or clinical signs of articular cartilage injury occurred in this study throughout the follow-up period.

A variety of physical therapy interventions are currently used to treat frozen shoulder, including the application of heat or ice, ultrasound therapy, interferential therapy, transcutaneous electrical nerve stimulation, active and passive ROM exercise, static stretching or stretching using proprioceptive neuromuscular facilitation techniques, and mobilization techniques \[[@pone.0118217.ref002],[@pone.0118217.ref005],[@pone.0118217.ref007],[@pone.0118217.ref009],[@pone.0118217.ref034]\]. Bal et al. \[[@pone.0118217.ref035]\] concluded that exercise therapy was critically important in the treatment of frozen shoulder. The authors suggested the importance of patient education regarding improvements in shoulder ROM. Stretching should be the focus of treatment, but it should not be performed beyond the limits of the available shoulder ROM. In this study, the immediate pain relief and increased ROM could be explained by the effects of the lidocaine injection. However, the effects disappeared in a few hours, and the long-term effectiveness was mostly a result of physiotherapy.

Study limitations {#sec017}
-----------------

The present study has several limitations. First, we did not include an untreated control group for ethical and practical reasons. However, because most of our subjects had had shoulder pain for longer than 3 months without signs of spontaneous improvement, we believed that spontaneous recovery in a short period was unlikely. Second, we were unable to blind the treating physical therapist, so potential bias may have occurred during physical therapy. Third, a placebo effect may have occurred in the injection group. Fourth, a previous study showed that the accuracy of palpation-guided injection of the shoulder ranged from 74% to 91%; injection under ultrasound guidance may increase this accuracy \[[@pone.0118217.ref036]\]. However, in this study, the pain level during capsule stretching immediately after the injection decreased by more than 50%; thus, accurate injection can be confirmed. Fifth, our sample size may also be one of the study's limitations. Finally, we did not adopt a more advanced randomization scheme, such as stratified randomization, because it might have required more administrative effort, more clinical visits, and a longer recruitment time than a simple random sample, and this might have increased the difficulty of the whole process of patient recruitment.

Conclusions {#sec018}
===========

In conclusion, this study demonstrated that intraarticular injection of 3 ml of 1% lidocaine into the affected shoulder immediately before a physiotherapy session can relieve pain during stretching or joint mobilization and thus enhances the treatment effects of physiotherapy for a frozen shoulder. However, in consideration of possible articular cartilage toxicity by local anesthetics, the number of injections should be kept as low as possible.
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